B8F — Biofrontera AG Income Statement
0.000.00%
Last trade - 00:00
- €19.91m
- €17.69m
- €25.74m
- 35
- 68
- 13
- 30
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 21.1 | 31.3 | 30.3 | 28.8 | 25.7 |
Cost of Revenue | |||||
Gross Profit | 16.7 | 26.4 | 26.8 | 24.9 | 21 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 39.6 | 39.8 | 38 | 4.13 | 24.6 |
Operating Profit | -18.5 | -8.56 | -7.61 | 24.7 | 1.12 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.3 | -4.78 | -12.7 | 35.7 | -43.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.88 | -7.36 | -13 | 33.9 | -44.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -8.88 | -7.36 | -13 | 38.3 | -44.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.88 | -7.36 | -13 | 38.3 | -44.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.194 | -0.364 | -0.23 | 0.211 | -0.768 |
Dividends per Share |